<DOC>
	<DOCNO>NCT01490736</DOCNO>
	<brief_summary>The purpose study determine safety photodynamic therapy ( PDT ) lemuteporfin topical solution ( LTS ) healthy subject subject mild acne .</brief_summary>
	<brief_title>Phase 1/2 Sequentially Staged Safety Study Healthy Subjects Subjects With Mild Acne</brief_title>
	<detailed_description>This sequentially stag ( Stage 1-4 ) , proof concept study assess safety photodynamic therapy ( PDT ) lemuteporfin topical solution ( LTS ) healthy subject subject mild acne . Approximately 12 subject enrol Stage 1 order determine maximum tolerate light dose follow LTS application . Up 90 subject mild acne enrol Stage 2 order ass safety PDT follow single LTS application . Up 50 subject enrol Stage 3 order ass safety PDT follow repeat LTS application . Up 40 subject enrol Stage 4 ass multiple treatment LTS-PDT .</detailed_description>
	<criteria>Stage 1 : healthy subject Stage 14 : male female subject age 18 year old Stage 2 : subject sebum excretion rate 4 high forehead Stage 24 : subject least 2 inflammatory acne lesion forehead Stage 34 : subject sebum excretion rate 5 high forehead Poor skin condition back ( Stage 1 ) face ( Stage 2 &amp; 3 ) Severe facial acne , acne fluminans/conglobata , nodulocystic acne Stage 24 : previous use Diane35 within 6 month Day 0 , systemic acne treatment systemic antibiotic treatment within 28 day Day 0 , topical acne treatment face within 14days Day 0 PDT face within 3 month Day 0 Stage 24 : previous treatment isotretinoin oral retinoids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Acne</keyword>
	<keyword>Sebum gland disease</keyword>
</DOC>